Showing 129–144 of 282 results
-
-
-
G280-9
The G280-9 peptide, a common melanoma gp100 epitope restricted by MHC-associated HLA-A2. The G280-9 sequence is unique because it could be recognized by cytotoxic T lymphocytes at very low concentrations, however it shows low total immunogenicity that may be attributable to relatively low affinity of this peptide for the HLA-A2.
-
-
Gastric Inhibitory Peptide (GIP), human
GIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42-amino-acid peptide hormone synthesized in and secreted from K cells in the intestinal epithelium. There are two major GIP molecular forms in circulation, GIP (1-42) and GIP(3-42). Previous studies have demonstrated that GIP (3-42) is a degraded form of GIP (1-42) by the enzyme DPPIV. GIP secretion is primarily regulated by nutrients, especially fat. GIP exhibits potent incretin activity in rodent and human subjects. The primary action of GIP is the stimulation of glucose-dependent insulin secretion. GIP may also play a role in adipocyte biology.
-
-
-
-
-
-
Glucagon-Like Peptide (GLP) I (7-37)
GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells. It is a potent insulinotropic hormone.
-
Glucagon-Like Peptide (GLP) II, human
Glucagon-like peptide 2 (GLP-2) is a recently identified intestinal epithelium-specific growth factor that has been shown to reduce the severity of inflammatory disorders of the intestine in rodent models. Currently Glucagon-Like Peptide 2 is used as a potential therapeutic agent for the human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency.
-
-
-
-
GP100 Intron 4 Peptide (VYFFLPDHL)
gp100/pmel, also known as pmel17, is a melanoma-associated differentiation antigen that is investigated as a target in melanoma immunotherapy.